Browsing by Yonsei Author : Chung, Hyun Cheol

eperson profile image
Chung, Hyun Cheol [정현철]
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (7404006815)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 434

This table browses all dspace content
Issue DateTitleJournal Title
2024Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinomaBIOORGANIC CHEMISTRY
2024First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine Against HER2-Positive Advanced Gastric Cancer CANCER RESEARCH AND TREATMENT
2024Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer StudyJOURNAL OF CLINICAL ONCOLOGY
2024Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II studyGASTRIC CANCER
2023Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialLANCET
2023Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer SCIENTIFIC REPORTS
2023Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response CELL REPORTS MEDICINE
2023Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy YONSEI MEDICAL JOURNAL
2023Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial JOURNAL FOR IMMUNOTHERAPY OF CANCER
2023Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction CancerJOURNAL OF CLINICAL ONCOLOGY
2023Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 studyCANCER
2023A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) CANCER RESEARCH AND TREATMENT
2023Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062 JAPANESE JOURNAL OF CLINICAL ONCOLOGY
2023Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial JOURNAL OF CLINICAL ONCOLOGY
2023Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea PALLIATIVE MEDICINE REPORTS
2023Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple CombinationJOURNAL OF GASTRIC CANCER
2022Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational BurdenCLINICAL CHEMISTRY
2022Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort AESMO OPEN
2022A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer NATURE COMMUNICATIONS
2022Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancerEUROPEAN JOURNAL OF CANCER
2022Probe-Based Confocal Laser Endomicroscopy versus White-Light Endoscopy with Narrow-Band Imaging for Predicting and Collecting Residual Cancer Tissue in Patients with Gastric Cancer Receiving Chemotherapy CANCERS
2022Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancerJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2022Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 StudyCLINICAL CANCER RESEARCH
2022Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study EUROPEAN JOURNAL OF CANCER
2022PD-L1 expression and overall survival in Asian and western patients with gastric cancerFUTURE ONCOLOGY
2022Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors NEURO-ONCOLOGY
2022Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors CANCERS
2022Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01)JOURNAL OF CLINICAL ONCOLOGY
2022Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trialJOURNAL OF CLINICAL ONCOLOGY
2022Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysisJOURNAL OF CLINICAL ONCOLOGY
2022MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in progressJOURNAL OF CLINICAL ONCOLOGY
2022Genomic profiling as a response predictor of second-line treatment in advanced gastric cancer patients: Post-hoc analyses of two phase Ib/II trialsJOURNAL OF CLINICAL ONCOLOGY
2022Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinomaJOURNAL OF CLINICAL ONCOLOGY
2022Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY
2022First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer ANNALS OF ONCOLOGY
2022Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma ESMO OPEN
2021The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer NATURE
2021Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion studyLANCET ONCOLOGY
2021Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsCLINICAL CANCER RESEARCH
2021Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancerCELLULAR ONCOLOGY
2021Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer CANCER MEDICINE
2021Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 GASTRIC CANCER
2021Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib plus capecitabine (N plus C) vs lapatinib plus capecitabine (L plus C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimensBREAST CANCER RESEARCH AND TREATMENT
2021Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade ResponsesHEPATOLOGY
2021Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations INVESTIGATIONAL NEW DRUGS
2021Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma ANNALS OF ONCOLOGY
2021Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in AsiaTARGETED ONCOLOGY
2021Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab GASTRIC CANCER
2021Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population GUT
2021Detection of asymptomatic recurrence improves survival of gastric cancer patients CANCER MEDICINE